Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in ...

Jennifer Halchak; VP, IR; Organon & Co. Kevin Ali; Chief Executive Officer, Director; Organon & Co. Matthew Walsh; Chief Financial Officer, Senior Vice President; Or ...

For recently acquired Tofidence, that product is manufactured in China, but we have inventory coverage offering us protection through 2025. The denosumab asset from Shanghai Henlius is not planned ...

For recently acquired Tofidence, that product is manufactured in China, but we have inventory coverage offering us protection through 2025. The denosumab asset from Shanghai Henlius is not planned ...

The First Circuit, in a closely watched securities case, reversed a $93 million summary judgment ruling for the Securities and Exchange Commission this April. The SEC's case against Commonwealth ...

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

Prior to Avtozma, the FDA approved two other Actemra biosimilars: Tofidence (tocilizumab-bavi) in September 2023 and Tyenne (tocilizumab-aazg) in March 2024. The introduction of Avtozma adds to the ...

Join us as we spotlight select chapters of Venable’s popular Advertising Law Tool Kit, which helps marketing teams navigate their organization’s legal risk. Telephone and text message ...

In another development, Organon has acquired the U.S. rights to TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen, further expanding its arthritis treatment portfolio. Furthermore, Biogen plans to ...

In another development, Organon has acquired the U.S. rights to TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen, further expanding its arthritis treatment portfolio. Furthermore, Biogen plans ...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE ...